Core Insights - The article discusses the transformation of Chinese companies, particularly those from Jinan, from being mere exporters to becoming integral players in global supply chains, emphasizing the shift from selling products to providing comprehensive solutions [1][4]. Group 1: Export Growth and Strategy - Jinan's total import and export value reached 258.81 billion yuan from January to November 2025, marking a 24.9% year-on-year increase, the highest in the province [1]. - Qilu Pharmaceutical has transitioned from exporting raw materials to finished pharmaceutical products, with 34 products now exported to the U.S., establishing a significant presence in major regulatory markets [2]. - In the first three quarters of the year, Qilu Pharmaceutical achieved an export value of 869 million USD, reflecting an 11% increase [2]. Group 2: Innovative Business Models - Qilu Pharmaceutical's ability to provide a reliable management system has allowed it to be recognized as a trusted solution provider, enhancing its international standing [2]. - Jinan Kehong Biopharmaceutical has adopted a "global selection + global coverage" model, establishing a network across nearly 70 countries and regions, and integrating over 40 domestic pharmaceutical products into its offerings [3]. Group 3: Localized Operations and Ecosystem Building - China National Heavy Duty Truck Group has shifted its business model from trade to a comprehensive global operation covering R&D, manufacturing, and service, reflecting a significant change in operational logic [4][5]. - The company has localized its workforce in Australia, achieving over 50% local team composition, which has helped it quickly rise to a top-five market position [5]. Group 4: Advanced Technology and Market Positioning - Shandong Tianyue Advanced Technology has emerged as a leader in the silicon carbide substrate market, achieving a 47.53% share of overseas revenue and establishing partnerships with top semiconductor manufacturers [7]. - Huaxi Biotechnology has invested significantly in a synthetic biology pilot transformation platform, aiming to address global challenges in biomanufacturing and expand its market presence [8][9]. Group 5: Comprehensive Solutions and Industry Integration - Shandong High-Speed Group is transitioning from an engineering contractor to a comprehensive solution provider, exemplified by its involvement in high-profile projects in Serbia and Bangladesh [6]. - The company has developed a collaborative ecosystem with five regional companies and ten specialized firms to support local enterprises in international markets [6].

Core Insights - By 2025, China's innovative pharmaceutical industry is projected to be the second largest globally, with approximately 30% of new drugs in development being from China, and the total amount of licensing agreements for domestic innovative drugs exceeding $100 billion, doubling from 2024 [1] - The Economist highlights that Chinese innovative drugs are at a critical point of globalization, with significant increases in global market share for Chinese pharmaceutical companies, and stock prices of Chinese biotech firms outperforming their US counterparts [1] - The rapid development is attributed to a decade of regulatory reforms, an ecosystem fostering innovation, and the advantages of China's large population and manufacturing capabilities [1] Industry Challenges - Despite impressive growth, the total market capitalization of Chinese biotech companies is only 15% of their US counterparts, with upfront licensing fees typically two-thirds lower than global averages [1] - Some pharmaceutical companies struggle with commercialization capabilities, which limits their potential value realization [1] Value Restructuring - Leading innovative pharmaceutical companies are advancing towards the top of the global value chain, with firms like Kangfang Biotech transitioning from licensing revenue to self-driven commercialization [2] - Companies are focusing on both global product development and building scalable commercialization platforms, which is becoming a core strategy for Chinese biotech firms to evolve into biopharma [2] Global Innovation Landscape - Chinese pharmaceutical companies are shifting from being fast followers to first movers, evidenced by significant business development deals with major international firms [3] - The mRNA technology sector is also seeing growth, with multiple companies advancing clinical trials and product development [3] mRNA Technology Potential - The value of mRNA technology is becoming increasingly evident, with major collaborations and acquisitions highlighting its potential [4] - Companies are pursuing dual strategies of in-licensing and out-licensing innovative assets to establish a strong global presence [4] Commercialization Challenges - The approval rate for new drugs is low, with only about 5% of drugs entering clinical trials successfully reaching the market, and only 20% of those achieving profitability [6] - Successful commercialization is critical for innovative drug companies, as it provides funding for future research and development [7] Market Dynamics - The traditional division of labor in the biopharmaceutical industry is evolving, with biotech companies gaining more negotiating power and opportunities for commercialization [9] - The market is expected to consolidate around platform companies with revenues between $5 billion and $10 billion, with a focus on integrating commercial strategies for innovative drugs [9] Commercialization Strategies - Companies like Cloudtop New Horizon are establishing integrated commercialization systems to enhance product growth and are actively pursuing partnerships to expand their market reach [10] - The company plans to introduce 3-5 significant products annually and aims to achieve substantial revenue growth by 2030 [10] Industry Evolution - The Chinese innovative pharmaceutical industry is undergoing a comprehensive upgrade, reshaping its value structure and positioning itself as a key player in the global biopharmaceutical landscape [11] - This transformation is moving China from a follower to a significant contributor and standard-setter in global biopharmaceutical innovation [11]

证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 科兴生物制药股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会 会议资料 $$=0{\exists}\exists\neq+{\exists}$$ | 2025 | 年第三次临时股东会会议须知 1 | | --- | --- | | 2025 2025 | 年第三次临时股东会会议议程 3 年第三次临时股东会会议议案 4 | | | 关于续聘 2025 年度审计机构的议案 5 | 科兴生物制药股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议须知 七、股东应在大会主持人点名后有序进行发言。发言内容应围绕股东会的议 案阐述观点和建议，每位股东发言的时间原则上不超过五分钟。 八、大会主持人可指定有关人员有针对性地回答股东提出的问题，与本次会 科兴生物制药股份有限公司 2025 年第三次临时股东会会议资料 为了维护科兴生物制药股份有限公司（以下简称"公司"或"本公司"）股 东的合法权益，确保股东会的正常秩序、议事效率，根据有关法律法规及《科兴 生物制药股份有限公司章程》（以下简称"《公 ...

Group 1 - The company will hold its third extraordinary general meeting on December 31, 2025, to review two proposals [1] - The first proposal involves reallocating 109.15 million yuan of raised funds and 15.87 million yuan of income from the "Drug Production Base Expansion Project" to the "R&D Center Upgrade Project," increasing the total fundraising amount to 472.48 million yuan and extending the implementation period to December 31, 2028 [1] - The second proposal is to reappoint Crowe Horwath as the auditing firm for the 2025 fiscal year, with the audit fee remaining at 1.3 million yuan, consistent with 2024 [1]

Core Viewpoint - The innovative drug sector in the Hong Kong stock market has shown remarkable performance, with biopharmaceutical B shares increasing by 119% year-to-date, and 25 out of 51 component stocks doubling in value [1] Group 1: Industry Insights - The CDMO industry has reached a performance bottom and is expected to continue strong growth through 2026, driven by new orders and robust R&D demand for new molecules [1] - The ADC (Antibody-Drug Conjugate) sector is highlighted as a high-barrier area, with Easton Pharmaceuticals demonstrating comprehensive service capabilities in this field [3][4] Group 2: Company Developments - Easton Pharmaceuticals has successfully assisted its partner Lepu Biopharma in obtaining NMPA approval for the first commercial ADC drug "Meiyouheng®," marking a significant milestone as the first EGFR-targeted ADC approved globally [3][4] - The company has established a one-stop ADC service platform, enabling seamless integration from raw material production to commercial manufacturing, which is crucial for the success of complex projects [4] Group 3: Financial Performance - Easton Pharmaceuticals has crossed the breakeven point since its strategic transformation, with a revenue of 489 million yuan in the first half of 2025 and a 25% year-on-year increase in net cash flow from operating activities [8] - The company has a high customer satisfaction rate, with a 73% repurchase rate and 200 million yuan in signed but uncompleted orders as of mid-2025 [9] Group 4: Competitive Advantages - The company possesses a unique "platform-type" capability that creates a significant competitive moat, particularly in the ADC sector, which is characterized by high growth potential [8] - Easton Pharmaceuticals' comprehensive capabilities in managing complex molecules from clinical development to commercialization have been validated through the successful launch of the global first EGFR ADC [11]

Core Viewpoint - Kexing Pharmaceutical's subsidiary has made significant progress in the field of recombinant type III collagen, with its product entering clinical trials, indicating a strong potential in the aesthetic medicine market [1][4]. Group 1: Product Development and Clinical Trials - Kexing Medical's recombinant type III humanized collagen product has passed clinical trial registration and has begun enrolling participants for its first trial [1]. - The product aims to treat dynamic wrinkles on the forehead through a clinical study designed to evaluate its effectiveness and safety [1][2]. - The company has also submitted a registration application for its second-class medical device, a collagen dressing [1]. Group 2: Technological Advantages and Market Potential - The recombinant type III collagen is derived from advanced biotechnology, ensuring high biocompatibility and bioactivity, which mitigates the risk of immune rejection associated with traditional animal-derived collagen [2]. - This collagen type is crucial for youthful skin and addresses aging signs such as wrinkles, making it a focal point in aesthetic medicine [2]. - The market for recombinant type III collagen in aesthetic applications is expanding rapidly, with a projected retail market size for aesthetic injectables in China expected to grow from 309 billion yuan in 2019 to 670 billion yuan in 2023, reflecting a compound annual growth rate (CAGR) of 21.4% [3]. Group 3: Strategic Positioning and Future Outlook - Kexing Medical has previously launched products in the consumer sector, including collagen masks and serums, which have gained popularity in Southeast Asia [4]. - The entry into clinical trials for the recombinant collagen product marks a significant milestone in the company's R&D and commercialization efforts in the aesthetic field [4]. - The company plans to continue focusing on the aesthetic medicine sector, emphasizing technological innovation and the development of high-quality products to meet market demands [5].

证券日报网讯 12月15日晚间，科兴制药发布公告称，公司将于2025年12月31日召开2025年第三次临时 股东会。 ...

关于科兴生物制药股份有限公司 变更部分募集资金用途及部分募投项目延期的核查意见 中信建投证券股份有限公司（以下简称"中信建投"或"保荐人"）作为科 兴生物制药股份有限公司（以下简称"科兴制药"或"公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上市公 司募集资金监管规则》《上海证券交易所科创板股票上市规则》和《上海证券交 易所科创板上市公司自律监管指引第1号—规范运作》等有关规定，对科兴制药 变更部分募集资金用途及部分募投项目延期事项进行了核查，具体情况如下： 一、变更募集资金投资项目的概述 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655 号）同意，公司首次公开发 行人民币普通股 4,967.5300 万股，每股面值人民币 1.00 元，每股发行价为人民 币 22.33 元，本次发行募集资金总额为 1,109,249,449.00 元，扣除保荐承销等发 行费用 114,608,529.84 元，募集资金净额为 994,640,919.16 元。 上述募集资金已全部到位，经大华会计师事务所（特殊 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-100 科兴生物制药股份有限公司 关于变更部分募集资金用途及部分募投项目延期的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟变更的募集资金投资项目（以下简称"募投项目"）：科兴生物制药股 份有限公司（以下简称"公司"）拟将"药物生产基地改扩建项目"的部分募集资 金变更至"研发中心升级建设项目" 的研发项目临床试验投入。 本次拟变更的募投项目金额为 12,502.00 万元，包括 10,915.22 万元募 集资金及该项目募集资金产生的利息收入、理财收益净额 1,586.78 万元（截 至 2025 年 11 月 30 日的金额，实际金额以资金转出当日计算利息收入后的剩 余金额为准，下同）。 公司募集资金投资项目的募集资金投资总额、实施主体不变，本次变 更部分募集资金用途事项不构成关联交易，不涉及新增募投项目。 募集资金投资项目基本情况表 单位：万元 币种：人民币 | 发行名称 | 2020 年首次公开发行股份 | | | | --- | ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-101 1、基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙） 成立日期：1981 年【工商登记：2011 年 12 月 22 日】 科兴生物制药股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：致同会计师事务所（特殊普通合伙）（以 下简称"致同所"） 科兴生物制药股份有限公司（以下简称"公司"）于2025年12月13日召开第 三届董事会第四次会议，审议通过了《关于续聘2025年度审计机构的议案》，同 意续聘致同会计师事务所（特殊普通合伙）为公司2025年度审计机构。前述议案 尚需提交公司股东会审议，具体情况如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO0014469 截至 2024 年末，致同会计师事务所（特殊普通合伙）（以下简称"致同所 ...